Five Under 5: Top Oncology Videos for the Week of 10/26

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis: Akriti G. Jain, MD

Akriti G. Jain, MD, of the Cleveland Clinic, discussed unmet needs in the myeloproliferative neoplasms paradigm, with a focus on JAK inhibition in polycythemia vera and myelofibrosis. Jain highlighted that the only potential cure for these disorders is a stem cell transplant and emphasized the need to determine whether disease modification can occur without transplant, including whether reductions in JAK2, CALR, or MPL allele burden, reversal of fibrosis, or decreases in cytokines represent meaningful modification. She noted that further research is needed to elucidate the role of combination therapies and how to safely bridge patients to transplant. Jain underscored that defining these parameters is imperative to improving outcomes and addressing the significant unmet need in these diseases.

Obrixtamig Plus Atezolizumab/Chemo in First-Line ES-SCLC: Solange Peters, MD, PhD

Solange Peters, MD, PhD, of Lausanne University Hospital, discussed data from the phase 1 DAREON-8 trial (NCT06077500) examining obrixtamig (BI 764532) with carboplatin, etoposide, and atezolizumab (Tecentriq) as frontline treatment in patients with extensive-stage small cell lung cancer (ES-SCLC). Peters noted that the dose-escalation portion of the research showed a manageable safety profile, with obrixtamig-related adverse effects reported in 96% of patients. The maximum tolerated dose of the agent was not reached. Among 28 evaluable patients, the confirmed overall response rate was 68% and the disease control rate was 89%; the median duration of response was 7.3 months. The 3-, 6-, and 9-month progression-free survival rates were 96%, 73%, and 52%, respectively. She emphasized that future analyses would shed light on whether obrixtamig is best administered immediately at day 1 cycle 1 or reserved for maintenance or second-line therapy to guide phase 3 trial design.

Clinical Implications of Targeted Therapies in Ovarian Cancer: Sarah Lynam, MD

Sarah Lynam, MD, of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, discussed the clinical applicability of mirvetuximab soravtansine-gynx (Elahere) and fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) for ovarian cancer. Lynam shed light on data from the phase 2 DESTINY-PanTumor02 trial (NCT04482309) and phase 3 MIRASOL trial (NCT04209855), emphasizing the importance of biomarker testing for HER2 and folate receptor α expression to inform treatment selection. She noted that mirvetuximab soravtansine is commonly associated with myelosuppression, anemia, blood dyscrasias, gastrointestinal events, and ophthalmologic toxicities, and trastuzumab deruxtecan carries a higher risk of pulmonary toxicity, including pneumonitis. Lynam underscored that understanding these safety profiles and individualized expression patterns helps clinicians sequence therapies appropriately and optimize decisions for patients with recurrent ovarian cancer.

PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC: Scott T. Tagawa, MD

Scott T. Tagawa, MD, MS, FACP, FASCO, of NewYork-Presbyterian – Weill Cornell Medical Center, discussed the phase 3 PSMAddition trial (NCT04720157) examining lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Tagawa explained that the study added up to 6 cycles of lutetium Lu 177 vipivotide tetraxetan to the standard backbone of an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in prostate-specific membrane antigen–positive patients. Data shared during the 2025 ESMO Congress indicated that those who received the combination (n = 572) achieved a median radiographic progression-free survival (rPFS) that was not reached (NR) vs NR with ARPI plus ADT; the hazard ratio was 0.72, translating to a 28% reduction in the risk of death or radiographic progression. Tagawa concluded that adding lutetium Lu 177 vipivotide tetraxetan to standard therapy offers a clinically meaningful improvement in rPFS for this patient population.

Role of SABR in Non–Small Cell Lung Cancer Management: Percy Lee, MD

Percy Lee, MD, of City of Hope, discussed the use of stereotactic ablative body radiotherapy (SABR) in patients with non–small cell lung cancer (NSCLC). He noted that SABR is a noninvasive treatment option suitable for most anatomical regions, such as the brain, chest, abdomen, and pelvis, and can often be delivered using standard radiation technology. However, in special cases where tumors are in difficult-to-treat locations—particularly near sensitive tissues—advanced approaches like proton therapy or MRI-guided SABR provide substantive benefit. Lee shared that City of Hope employs MRI-guided SABR for these scenarios. He emphasized that local therapies like SABR are appropriate for those with limited metastatic disease per ESTRO-ASTRO Consensus guidelines, ensuring all lesions are technically treatable by local modalities such as SABR, surgery, or ablation.